Bristol Myers Squibb (BMY) Other Non-Current Assets (2009 - 2026)

Bristol Myers Squibb has disclosed Other Non-Current Assets across 18 years of filings, most recently posting $6.1 billion for Q1 2026.

• In Q1 2026, Other Non-Current Assets rose 3.68% year-over-year to $6.1 billion; the TTM figure through Mar 2026 stood at $6.1 billion (up 3.68% YoY), while the FY2025 annual figure was $6.5 billion, up 6.04% from the prior year.
• Other Non-Current Assets declined to $6.1 billion in Q1 2026, from $6.5 billion in the prior quarter.
• Over the last five years, Other Non-Current Assets for BMY reached as high as $6.5 billion in Q4 2025 and fell as low as $53.0 million in Q1 2023.
• The 5-year median for Other Non-Current Assets is $5.9 billion (2025), against an average of $3.9 billion.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets tumbled 97.06% — and 2024, when it soared 11354.72%.
• A 5-year view of Other Non-Current Assets shows it stood at $4.9 billion in 2022, then advanced by 8.7% to $5.4 billion in 2023, then rose by 13.69% to $6.1 billion in 2024, then advanced by 6.04% to $6.5 billion in 2025, then slipped by 6.05% to $6.1 billion in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $6.1 billion, $6.5 billion, and $6.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.